CYTK
NASD Cytokinetics, Incorporated$65.60 ↑ +0.00 (+0.00%) Trading Up from the previous close of $65.60, $1.31 below the day’s high of $66.91
- YTD change
- +3.24%
- vs 20-day SMA
- -5.47%
- vs 200-day SMA
- -6.46%
Price ranges
Price & Performance
+0.66 (+1.02%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 40.5% away from all-time highs of $110.25
- CYTK is up 3% since the beginning of the year
- CYTK is up 16% over the past 12 months
- CYTK is down 9% over the past 1 month
- 13% of all CYTK investors are betting against CYTK
CYTK reads poor: price sits below both the 20- and 200-day averages, the 12-month move is +15.1%.
- Previous minute
- +$0.00
- Last hour
- -$0.41
- Last 5 days
- -0.09%
- vs 8-day SMA
- -0.43%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
